Core Viewpoint - Reborn Bio-B (06938) has seen a stock increase of over 5%, currently trading at 72.45 HKD, following the announcement of its RBD5044 injection receiving implied approval for Phase II clinical trials from the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - The small nucleic acid drug sector is experiencing significant global growth, transitioning from technology validation to accelerated clinical realization and commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically, the number of research pipelines ranks second only to the United States, addressing multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Notable collaborations include over 9 billion USD in cumulative partnerships between WuXi AppTec and Novartis, and a 2 billion USD platform licensing deal between Reborn Bio and Boehringer Ingelheim [1] - Traditional pharmaceutical companies like China National Pharmaceutical Group are rapidly positioning themselves through acquisitions, indicating a positive development trend in the industry [1]

Core Viewpoint - Reborn Bio-B (06938) shares rose over 5%, currently up 5.62% at HKD 72.45, with a trading volume of HKD 6.483 million, following the announcement of the II phase clinical trial approval for its self-developed RBD5044 injection by the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - According to Guosheng Securities (002670), small nucleic acid drugs are entering a robust global development phase, transitioning from technical validation to clinical realization and accelerated commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically yet, the number of research pipelines ranks second to the U.S., covering multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Significant collaborations have emerged, such as the over USD 9 billion partnership between WuXi AppTec and Novartis, and a USD 2 billion platform licensing deal between Reborn Bio and Boehringer Ingelheim, indicating a positive development trend in the industry [1]

Core Insights - Johnson & Johnson (JNJ) has a diverse revenue stream in its Innovative Medicine division, with sales reaching $60.4 billion in 2025, reflecting a 5.3% operational growth and a 4.1% organic growth despite the loss of exclusivity for Stelara [1][10] Group 1: Sales Performance - The Innovative Medicine segment achieved over $15 billion in sales for three consecutive quarters in 2025, marking the first time it surpassed $60 billion in full-year sales [2] - Key products such as Darzalex, Tremfya, and Erleada contributed significantly to growth, with Darzalex sales increasing by 23.0% to $14.35 billion, Erleada by 19.2% to $3.57 billion, and Tremfya by 40.5% to $5.2 billion [6][9] - The decline in Stelara sales by 41.3% to $6.08 billion in 2025 due to its loss of exclusivity negatively impacted the segment's growth by 1110 basis points [4][5] Group 2: Future Outlook - J&J anticipates accelerated growth in the Innovative Medicine segment in 2026, driven by key products and new launches, with expected growth of 5% to 7% from 2025 to 2030 [7][9] - The company expects a more pronounced impact from new products in 2026, including Rybrevant and Caplyta, following approvals in 2025 [7] - However, the impact of generic competition is expected to intensify in 2026, particularly for Stelara, Simponi, and Opsumit as they lose patent protection [8] Group 3: Competitive Landscape - J&J operates in key areas of immunology and oncology, facing competition from major drugmakers such as Novartis, AstraZeneca, AbbVie, and Amgen [10][11] Group 4: Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 55.6% over the past year compared to an 18.0% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 20.63, higher than the industry average of 18.76 and above its five-year mean of 15.65 [14] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.48 to $11.54, indicating positive sentiment [16]

Industry Overview - The global oncology market is undergoing rapid transformation due to increasing cancer incidence, demographic changes, and scientific advancements, with an estimated 2.1 million new cancer diagnoses and over 626,000 cancer-related deaths expected in the U.S. in 2026 [2] - Lifestyle-related risk factors and demographic shifts are contributing to a rise in cancer prevalence, leading to sustained growth in oncology healthcare spending [2] Innovation in Cancer Treatment - Advances in immunotherapies, targeted medicines, and personalized vaccines are reshaping cancer treatment, moving beyond traditional chemotherapy and radiation [3] - Immune-based approaches, such as checkpoint inhibitors and CAR-T therapies, utilize the immune system to target tumors, while targeted therapies focus on specific molecular and genetic disease drivers [3] - Technologies like genomic sequencing and AI are enhancing biomarker discovery and patient stratification, leading to earlier diagnoses and improved survival rates across various cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, and Pfizer, are investing heavily in oncology pipelines, developing new therapies such as antibody-drug conjugates and next-generation immuno-oncology treatments [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing deals, and acquisitions [5] Market Resilience - The oncology sector is viewed as one of the most resilient and attractive segments of the global healthcare market for long-term investors, supported by ongoing innovation and favorable reimbursement trends [6] Company Highlights - **ImmunityBio**: Its lead drug, Anktiva, approved in April 2024, generated $113 million in preliminary sales in 2025, with a 750% increase in volumes. The drug is under review in the EU and is being evaluated for expanded use in various cancers [8][9] - **Arcus Biosciences**: Developing casdatifan, a potential best-in-class HIF-2a inhibitor for treating clear cell renal cell carcinoma, with a market opportunity of over $5 billion. Multiple data readouts are expected in 2026 [10] - **Allogene Therapeutics**: Focused on genetically engineered T-cell therapies, with lead candidate cema-cel in a pivotal phase II study for large B-cell lymphoma. Another candidate, ALLO-316, shows early anti-tumor activity in advanced renal cell carcinoma [12][13]

Core Viewpoint - There is a potential opportunity for value investing within the pharmaceutical industry, specifically with Novartis (NVS) stock [1] Company Analysis - Novartis is highlighted as a stock that may be undervalued amidst the current focus on tech and AI companies [1] - The analysis emphasizes the importance of earnings, technological disruption, policy shifts, and capital flows in identifying mispriced opportunities in the market [1] Investment Strategy - The approach combines top-down macroeconomic analysis with bottom-up stock selection and real-time positioning [1] - The analyst shares insights on high-conviction ideas and contrarian views, focusing on both growth and value names [1]

Core Insights - Novartis AG reported fourth-quarter 2025 net sales of $13.34 billion, a 1% year-over-year increase, but below Wall Street's estimate of $13.78 billion [1] - On a constant-currency basis, sales decreased by 1% [1] - The company faced a significant negative impact from generic competition, which reduced sales by 15 percentage points, including a 3 percentage point impact from revenue deduction adjustments in the U.S. related to Entresto and Promacta [1] Financial Performance - Pricing pressures negatively impacted sales by 4 percentage points, while currency fluctuations had a positive impact of 2 percentage points [2] - Core operating income increased by 1% to $4.93 billion, with a core operating income margin of 37.0%, reflecting a slight increase of 0.1 percentage points [2] - The growth in core operating income was supported by higher government grant income and lower selling, general, and administrative (SG&A) expenses, although this was partially offset by increased research and development (R&D) expenses [2] Product Performance - Strong demand for key therapies contributed to growth, with Kisqali sales rising 44% to $1.32 billion, Kesimpta increasing 27% to $1.23 billion, and Cosentyx revenue up 11% to $1.81 billion [3] - Scemblix saw an 87% increase to $391 million, while Pluvicto advanced 70% to $605 million [3] Future Outlook - For fiscal 2026, Novartis anticipates low single-digit growth in net sales, while core operating income is expected to decrease in the low single digits [5] - The incoming CFO indicated that adjusted operating income is projected to grow significantly in the second half of 2026, which is expected to positively impact 2027 and beyond [5] - Novartis shares rose 1.79% to $152.54, reaching a new 52-week high [5]

Core Insights - Novartis AG reported fourth-quarter core earnings per share of $2.03, exceeding the Zacks Consensus Estimate of $1.99 and up from $1.98 a year ago [1][7] - Core net income decreased by 1% to $3.9 billion, while revenues of $13.3 billion fell short of the Zacks Consensus Estimate of $13.7 billion, despite a 1% year-over-year increase [2][7] - The company faced revenue pressure from generic competition for key drugs Entresto and Promacta, leading to a 1% decline in sales on a constant currency basis [2][26] Financial Performance - Core operating income improved by 1% to $4.9 billion, supported by higher government grant income and lower SG&A expenses, although offset by increased R&D expenses [19] - For 2025, Novartis reported sales growth of 8% to $54.53 billion, surpassing the Zacks Consensus Estimate, with core EPS increasing by 17% to $8.98 [20] - Guidance for 2026 indicates low single-digit growth in net sales on a constant currency basis, with core operating income expected to decline in low single digits [21] Drug Performance - Cosentyx sales rose 11% to $1.8 billion, driven by strong demand across all regions [5] - Kisqali sales surged 44% to $1.32 billion, although it missed estimates, with underlying global growth at 54% [6][8] - Entresto sales plummeted 45% to $1.2 billion due to generic competition, while Promacta sales fell 63% to $226 million [8][13] - Pluvicto sales increased by 70% to $605 million, driven by strong demand following recent approvals [11] - Kesimpta sales grew 27% to $1.2 billion, while Jakavi sales increased by 8% to $555 million [10][12] Strategic Updates - Novartis announced plans to acquire Avidity Biosciences for $12 billion to enhance its late-stage neuroscience pipeline [22][23] - The acquisition aims to strengthen the company's position in addressing genetic neuromuscular diseases [28] - A collaboration agreement with the U.S. government was established to reduce drug prices while supporting ongoing investments in manufacturing and R&D [25] Market Position - Novartis shares have gained 42.1% over the past year, outperforming the industry growth of 19% [2] - The company is navigating significant patent expirations, with a focus on key growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix [26][27]

Financial Data and Key Metrics Changes - Novartis achieved high single-digit sales growth of 8% for the full year 2025, with core operating income increasing by 14% to CHF 21.9 billion, achieving a core margin of 40.1% two years ahead of plan [5][34][36] - In Q4, sales declined by 1% due to gross-to-net impacts and the loss of exclusivity for Entresto, while core operating income increased by 1% [6][34] - Core EPS rose by 17% to $8.98, with free cash flow reaching an all-time high of CHF 17.6 billion, an 8% increase [37][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [7][8] - Kesimpta achieved 36% growth to $4.4 billion, with a 27% increase in Q4 [10][11] - Pluvicto reached $2 billion in sales, showing 42% constant currency growth, primarily driven by a 75% increase in the US [12][13] - Leqvio reached blockbuster status with 57% growth for the year and 46% in Q4 [14] - Scemblix also achieved blockbuster status with 87% growth in Q4 [15][16] Market Data and Key Metrics Changes - Novartis reported strong performance in key markets, with Kisqali leading in early breast cancer settings in Germany with over 80% NBRX share [8] - Kesimpta is leading in 9 out of 10 major markets outside the US [11] - Pluvicto has secured approvals in Japan and China, with expectations for strong growth in these markets [12] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement power [7] - The company is committed to maintaining a strong pipeline with 7 pivotal readouts expected in 2026, which could strengthen midterm growth outlook [31][49] - Novartis plans to continue investing in R&D, with over $10 billion allocated in 2025, and is focused on shareholder returns through dividends and share buybacks [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5%-6% sales CAGR from 2025 to 2030, despite anticipated generic impacts [42][48] - The company expects to return to a core margin of over 40% by 2029 [43] - Management highlighted the importance of pipeline assets and their potential to drive higher growth [49] Other Important Information - The company is transitioning leadership with Mukul Mehta set to take over as CFO in mid-March [5][41] - Novartis is focused on global health initiatives, including the development of new malaria treatments [30] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [54][56] Question: Commercial opportunities for remibrutinib in MS - Management acknowledged that while B-cell monoclonal antibodies will remain dominant, there is a significant market for oral options, especially for patients preferring non-injectable therapies [61] Question: Risks associated with Pelacarsen's study - Management expressed confidence in the study's design and powering assumptions, indicating that lower event rates may not pose significant risks [63]

Financial Data and Key Metrics Changes - Novartis achieved 8% sales growth and 14% core operating income growth for the full year 2025, with a core margin of 40.1%, reached two years ahead of plan [5][34][36] - For Q4, sales declined by 1%, while core operating income increased by 1%, with underlying growth of 3% when excluding one-time adjustments [6][38] - Core EPS rose 17% to $8.98, and free cash flow reached an all-time high of CHF 17.6 billion, growing 8% [34][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% to CHF 4.8 billion for the year, with Q4 growth at 44% [7][8] - Kesimpta grew 36% to $4.4 billion, with a 27% growth in Q4 [10][11] - Pluvicto reached $2 billion in sales, showing 42% constant currency growth [12] - Leqvio achieved blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Novartis reported strong growth in key markets, with Kisqali leading in early breast cancer settings in Germany with over 80% NBRX share [8] - Kesimpta is leading in 9 out of 10 major markets outside the U.S. [11] - Pluvicto has secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement power [7] - The company is committed to maintaining a strong pipeline with seven pivotal readouts expected in 2026 [31][49] - Novartis plans to continue investing in R&D, with over $10 billion allocated in 2025 [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5%-6% sales CAGR from 2025 to 2030, despite anticipated generic impacts [42][48] - The company expects to return to a core margin of over 40% by 2029 [43] - Management highlighted the importance of pipeline assets in driving future growth [49] Other Important Information - The company completed a CHF 15 billion share buyback program and proposed a dividend increase of 6% [40][27] - The transition of CFO from Harry Kirsch to Mukul Mehta was noted, with Kirsch acknowledging the company's transformation during his tenure [41] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management confirmed that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [54][56] Question: Commercial opportunities for remibrutinib in MS - Management indicated that while B-cell monoclonal antibodies will remain dominant, there is a significant market for oral options, especially for patients preferring non-injectable therapies [61] Question: Risks associated with Pelacarsen's event-based study - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [63]

Financial Data and Key Metrics Changes - Novartis achieved high single-digit growth with an 8% increase in sales and a 14% rise in core operating income for the full year 2025, reaching a core margin of 40.1% [4][35] - For Q4, sales declined by 1%, while core operating income increased by 1%, with core EPS rising 2% to $2.03 [5][38] - Free cash flow reached an all-time high of CHF 17.6 billion, growing 8% year-over-year [35][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [6][7] - Kesimpta saw a 36% increase to $4.4 billion, with a 27% growth in Q4 [10] - Pluvicto achieved $2 billion in global sales, with a 75% increase in the U.S. [12] - Leqvio reached blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Kisqali's U.S. sales growth was 62%, with over 80% NBRX share in Germany for early breast cancer [7][9] - Kesimpta is leading in NBRX share in 9 out of 10 major markets outside the U.S. [10] - Pluvicto secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] - Scemblix has a 41% NBRX share in the U.S. and 72% in the third-line setting across major markets [17] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement [6] - The company plans to continue investing in R&D while managing productivity improvements [43][44] - Novartis is committed to maintaining a 5%-6% sales CAGR from 2025 to 2030 [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit sales growth in 2026 despite anticipated challenges from generic entries [43][44] - The company expects to return to a core margin of over 40% by 2029 [44] - Management highlighted the importance of pipeline advancements and upcoming pivotal readouts in 2026 [32][50] Other Important Information - Novartis has completed its CHF 15 billion share buyback program and initiated a new CHF 10 billion program [41] - The proposed dividend for 2025 is CHF 3.70 per share, marking a 6% increase [41][42] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [53][54] Question: Commercial opportunities for remibrutinib in MS - Management indicated that the commercial opportunity will depend on data-driven results, with a significant market for oral options in MS [60][61] Question: Thoughts on Pelacarsen's event-based study risks - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [62][63] Question: Launch plans for Rhapsido and Ianalumab in an MFN world - Management acknowledged the importance of adjusting launch strategies for significant assets like Rhapsido and Ianalumab in the ex-U.S. market [73]